Asia-Pacific Adalimumab Market - Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Dec 2020
  • Asia-Pacific
  • 350 Pages
  • No of Tables: 168
  • No of Figures: 54

Asia-Pacific Adalimumab Market, By Indication (Rheumatoid Arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Non-Infectious Intermediate, Others), Type (Biologics, Biosimilars), Dosage Strength (40mg/0.4mlg, 80mg/0.8mlg, 20mg/0.2mlg, 10mg/0.1mlg, Others), Drug Type (Branded, Generics), Route of Administration (Parenteral, Oral), Population Type (Adults, Children), End User (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Direct Tenders, Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends & Forecast to 2027 

Asia-Pacific Adalimumab MarketMarket Analysis and Insights: Asia-Pacific Adalimumab Market

Asia-Pacific adalimumab market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.6% in the forecast period of 2020 to 2027 and is expected to reach USD 1,296.65 million by 2027. Increasing geriatric population and introduction to biosimilars are the major drivers which propelled the demand of the market in the forecast period.

Adalimumab is one of the monoclonal antibodies and is used for the treatment of certain autoimmune diseases involving rheumatoid arthritis and crohn's diseases among others. Adalimumab is an anti- TNF drug indicated for the treatment of inflammatory symptoms. The biologic of adalimumab is humira and various biosimilar drugs of humira are also available which involves exemptia, hyrimoz, cyltezo and hulio among several others. Adalimumab works by binding to the TNF factor-alpha which reduces the chances of the inflammatory response to autoimmune diseases. 

Adalimumab comprises features such as increasing need for better therapeutics options which will impact in launching new product by the manufacturers into the market which enhance its demand as well as increasing investment in research and development leads to the adalimumab market growth. Currently, various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative adalimumab which is expected to provide various other opportunities in the adalimumab market. However, high cost of drugs and side effects of drugs are expected to restraint the adalimumab market growth in the forecast period.

The Asia-Pacific adalimumab market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Asia-Pacific Adalimumab MarketAdalimumab Market Scope and Market Size  

The adalimumab market is segmented on the basis of indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

  • On the basis of indication, the adalimumab market the market is segmented into rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis, hidradenitis suppurativa, non-infectious intermediate and others. In 2020, rheumatoid arthritis is dominating the market because of increasing prevalence of rheumatoid arthritis. Moreover increasing geriatric population is also boosting the rheumatoid arthritis segment growth.   
  • On the basis of type, the adalimumab market is segmented into biologics and biosimilars. In 2020, biologics segment is dominating the market because of the presence of biologic drugs that is Humira all over the world and presence of few approved biosimilar drugs.
  • On the basis of dosage strength, the adalimumab market is segmented into 40mg/0.4ml, 80mg/0.8ml, 20mg/0.2ml, 10mg/0.1ml and others. In 2020, 40mg/0.4ml is dominating the market because majority of population or patients are suffering from several kids of inflammatory disease relying on 40mg dose as first line of therapy in order to achieve effective treatment.
  • On the basis of drug type, the adalimumab market is segmented into branded and generics. In 2020, branded segment is dominating the market because patients are more satisfied with the branded product; moreover AbbVie has marketing right for branded adalimumab which is Humira all over the world.
  • On the basis of route of administration, the adalimumab market is segmented into parenteral and oral. In 2020, parenteral segment is dominating the market because adalimumab is a human monoclonal antibody that provides with effective results when passes through the systemic circulation.
  • On the basis of population type, the adalimumab market is segmented into adults and children. In 2020, adults segment is dominating the market because adult populations have weak immune system and are more prone to inflammatory diseases.
  • On the basis of end user, the adalimumab market the market is segmented into hospitals, specialty clinics, home healthcare and others. In 2020, hospitals segment is dominating the market because patient suffering from inflammatory diseases frequently visits hospital in order to achieve effective drug administration via skilled professionals.
  • On the basis of distribution channel, the adalimumab market the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, direct tenders and others. In 2020, hospital pharmacies segment is dominating the market because adalimumab is only prescribed by the doctors, so one can only buy it from the hospital pharmacies at a reasonable price.

Asia-Pacific Adalimumab Market Country Level Analysis 

Adalimumab market is analyzed and market size information is provided by country, indication, type, dosage strength, drug type, route of administration, population type, end user and distribution channel as referenced above.

The countries covered in the Asia-Pacific adalimumab market report are the Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.  

Japan is leading the growth of the Asia-Pacific adalimumab market as the medication is dominating in this country due to rise in prevalence of precocious puberty and rising population of girls among several other health problems.  

The country section of the Asia-Pacific adalimumab market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Presence of Reimbursement and Exploration of Emerging Markets are Boosting the Market Growth of Adalimumab

Asia-Pacific adalimumab market also provides you with detailed market analysis for every country growth in Adalimumab industry with Adalimumab drugs sales, impact of advancement in the Adalimumab technology and changes in regulatory scenarios with their support for the Asia-Pacific adalimumab market. The data is available for historic period 2010 to 2018.   

Competitive Landscape and Adalimumab Market Share Analysis

Asia-Pacific adalimumab market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Asia-Pacific adalimumab market.   

The major companies which are dealing in the Asia-Pacific adalimumab market are AbbVie Inc., Boehringer Ingelheim International GmbH, CELLTRION INC., Samsung Bioepis (A Subsidiary of Samsung Biologics), Biogen, Innovent Biologics, Inc., Mylan N.V., Hetero Biopharma Ltd., Pfizer Inc., Zydus Cadila and Reliance Life Sciences (A Subsidiary of Reliance Industries Limited) many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the Adalimumab market.  

For instance,

  • In July 2019, CELLTRION INC. along with the Nan Fung Group established Vcell Healthcare Limited, a joint venture company for the development, manufacturing and commercialization of biosimilar products in China. This initiative allowed the company to develop world-class biosimilar products including adalimumab and hence helped it to strengthen its root in the adalimumab market. 
  • In January 2019, Coherus BioSciences signed a settlement agreement with AbbVie for the commercialization of CHS-1420, a biosimilar reference of HUMIRA. This settlement agreement allowed the company to achieve commercialization rights for its product in the U.S. This initiative helped the company to get ensure the future product launch.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the adalimumab market which also provides the benefit for organization to improve their offering for adalimumab.   

Customization Available: Asia-Pacific Adalimumab Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 ASIA- PACIFIC ADALIMUMAB MARKET, PIPELINE ANALYSIS

TABLE 2 BIOSIMILAR OF ADALIMUMAB LAUNCHED IN THE U.S.

TABLE 3 PREVALENCE AND INCIDENCE RATES OF RA WORLDWIDE (CASE PER 100 INHABITANTS)

TABLE 4 BIOLOGIC DRUGS SUBJECTED TO PATENT LOSS

TABLE 5 ALTERNATIVE DRUGS FOR INFLAMMATORY DISEASES TREATMENT

TABLE 6 ASIA- PACIFIC ADALIMUMAB MARKET, BY INDICATION 2019-2027 (USD MILLION)

TABLE 7 ASIA- PACIFIC RHEUMATOID ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 8 ASIA- PACIFIC ANKYLOSING SPONDYLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 ASIA- PACIFIC CHRONIC PLAQUE PSORIASIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 10 ASIA- PACIFIC CROHN’S DISEASE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 11 ASIA- PACIFIC ULCERATIVE COLITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 ASIA- PACIFIC PSORIATIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 13 ASIA- PACIFIC JUVENILE IDIOPATHIC ARTHRITIS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 14 ASIA- PACIFIC HIDRADENITIS SUPPURATIVA IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 15 ASIA- PACIFIC NONINFECTIOUS INTERMEDIATE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 ASIA- PACIFIC OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 17 ASIA- PACIFIC ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 18 ASIA- PACIFIC BIOLOGICS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 19 ASIA- PACIFIC BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 20 ASIA- PACIFIC BIOSIMILARS IN ADALIMUMAB MARKET, BY TYPE 2019-2027 (USD MILLION)

TABLE 21 ASIA- PACIFIC ADALIMUMAB MARKET, BY DOSAGE STRENGHT, 2019-2027 (USD MILLION)

TABLE 22 ASIA- PACIFIC 40MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 ASIA- PACIFIC 80MG/0.8ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 24 ASIA- PACIFIC 20MG/0.4ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 25 ASIA- PACIFIC 10MG/0.1ML IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 26 ASIA- PACIFIC OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 27 ASIA- PACIFIC ADALIMUMAB MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

TABLE 28 ASIA- PACIFIC BRANDED IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 ASIA- PACIFIC GENERICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 ASIA- PACIFIC GENERICS ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 31 ASIA- PACIFIC ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION 2019-2027 (USD MILLION)

TABLE 32 ASIA- PACIFIC PARENTERAL IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 ASIA- PACIFIC ADALIMUMAB MARKET, BY POPULATION TYPE, 2019-2027 (USD MILLION)

TABLE 34 ASIA- PACIFIC ADULTS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 ASIA- PACIFIC CHILDREN IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 ASIA- PACIFIC ADALIMUMAB MARKET, BY END USER, 2019-2027 (USD MILLION)

TABLE 37 ASIA- PACIFIC HOSPITALS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 ASIA- PACIFIC SPECIALTY CLINICS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 ASIA- PACIFIC HOME HEALTHCARE IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 ASIA- PACIFIC OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 ASIA- PACIFIC ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

TABLE 42 ASIA- PACIFIC HOSPITAL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 ASIA- PACIFIC RETAIL PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 ASIA- PACIFIC ONLINE PHARMACIES IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 ASIA- PACIFIC DIRECT TENDER IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 46 ASIA- PACIFIC OTHERS IN ADALIMUMAB MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 ASIA- PACIFIC ADALIMUMAB MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 48 ASIA- PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 49 ASIA- PACIFIC ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 50 ASIA- PACIFIC BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 51 ASIA- PACIFIC ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 52 ASIA- PACIFIC ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 53 ASIA- PACIFIC GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 54 ASIA- PACIFIC ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 55 ASIA- PACIFIC ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 56 ASIA- PACIFIC ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 57 ASIA- PACIFIC ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 58 JAPANADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 59 JAPANADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 60 JAPANBIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 61 JAPANADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 62 JAPANADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 63 JAPAN GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 64 JAPANADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 65 JAPANADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 66 JAPANADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 67 JAPANADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 68 CHINA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 69 CHINA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 CHINA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 CHINA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 72 CHINA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 73 CHINA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 74 CHINA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 75 CHINA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 76 CHINA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 77 CHINA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 78 SOUTH KOREA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 79 SOUTH KOREA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 SOUTH KOREA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 81 SOUTH KOREA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 82 SOUTH KOREA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 83 SOUTH KOREA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 84 SOUTH KOREA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 85 SOUTH KOREA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 86 SOUTH KOREA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 87 SOUTH KOREA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 88 AUSTRALIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 89 AUSTRALIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 AUSTRALIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 AUSTRALIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 92 AUSTRALIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 93 AUSTRALIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 94 AUSTRALIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 95 AUSTRALIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 96 AUSTRALIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 97 AUSTRALIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 98 INDIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 99 INDIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 INDIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 INDIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 102 INDIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 103 INDIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 104 INDIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 105 INDIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 106 INDIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 107 INDIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 108 SINGAPORE ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 109 SINGAPORE ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 110 SINGAPORE BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 111 SINGAPORE ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 112 SINGAPORE ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 113 SINGAPORE GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 114 SINGAPORE ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 115 SINGAPORE ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 116 SINGAPORE ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 117 SINGAPORE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 118 MALAYSIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 119 MALAYSIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 MALAYSIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 MALAYSIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 122 MALAYSIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 123 MALAYSIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 124 MALAYSIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 125 MALAYSIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 126 MALAYSIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 127 MALAYSIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 128 THAILAND ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 129 THAILAND ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 THAILAND BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 THAILAND ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 132 THAILAND ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 133 THAILAND GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 134 THAILAND ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 THAILAND ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 136 THAILAND ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 137 THAILAND ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 138 INDONESIA ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 139 INDONESIA ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 INDONESIA BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 INDONESIA ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 142 INDONESIA ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 INDONESIA GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 144 INDONESIA ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 145 INDONESIA ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 146 INDONESIA ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 INDONESIA ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 PHILIPPINES ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 149 PHILIPPINES ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 PHILIPPINES BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 PHILIPPINES ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 152 PHILIPPINES ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 153 PHILIPPINES GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 154 PHILIPPINES ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 155 PHILIPPINES ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 156 PHILIPPINES ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 157 PHILIPPINES ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 158 VIETNAM ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

TABLE 159 VIETNAM ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 160 VIETNAM BIOSIMILARS OF ADALIMUMAB MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 161 VIETNAM ADALIMUMAB MARKET, BY DOSAGE STRENGTH, 2018-2027 (USD MILLION)

TABLE 162 VIETNAM ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 163 VIETNAM GENERICS IN ADALIMUMAB MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 164 VIETNAM ADALIMUMAB MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 165 VIETNAM ADALIMUMAB MARKET, BY POPULATION TYPE, 2018-2027 (USD MILLION)

TABLE 166 VIETNAM ADALIMUMAB MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 167 VIETNAM ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 168 REST OF ASIA-PACIFIC ADALIMUMAB MARKET, BY INDICATION, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions